文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

1型糖尿病中调节性T细胞的失调与治疗前景

Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes.

作者信息

Syed Khaja Azharuddin Sajid, Binsaleh Naif K, Qanash Husam, Alshetaiwi Hamad, Ginawi Ibrahim Abdelmageed Mohamed, Saleem Mohd

机构信息

Department of Pathology, College of Medicine, University of Hail, 55476, Hail, Saudi Arabia.

Medical and Diagnostic Research Centre, University of Hail, 55476, Hail, Saudi Arabia.

出版信息

Acta Diabetol. 2025 Mar 21. doi: 10.1007/s00592-025-02478-3.


DOI:10.1007/s00592-025-02478-3
PMID:40116924
Abstract

Type 1 diabetes (T1D) is an autoimmune disease that selectively destroys β-cells in the pancreas that produce insulin. Several studies have implicated and elaborated the significant role of regulatory T cells (Tregs) in the pathogenesis of T1D. Tregs are a specialized subset of T cells and are critical regulators of peripheral self-tolerance. However, if the number, function, or stability of these cells is altered, it can lead to autoimmunity. This review summarizes the current knowledge and understanding about Treg function in both health and T1D, Tregs dysregulation, and various factors, including microRNAs, that affect their dysregulation in T1D. The review also focuses on the advantages and challenges of Treg-based therapies for T1D.

摘要

1型糖尿病(T1D)是一种自身免疫性疾病,它会选择性地破坏胰腺中产生胰岛素的β细胞。多项研究已经表明并阐述了调节性T细胞(Tregs)在T1D发病机制中的重要作用。Tregs是T细胞的一个特殊亚群,是外周自身耐受性的关键调节因子。然而,如果这些细胞的数量、功能或稳定性发生改变,就可能导致自身免疫。这篇综述总结了目前关于Tregs在健康和T1D中的功能、Tregs失调以及包括微小RNA在内的各种影响其在T1D中失调的因素的知识和理解。该综述还重点介绍了基于Tregs的T1D治疗方法的优势和挑战。

相似文献

[1]
Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes.

Acta Diabetol. 2025-3-21

[2]
Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.

Front Immunol. 2021

[3]
Antigen-Specific Treg Therapy in Type 1 Diabetes - Challenges and Opportunities.

Front Immunol. 2021

[4]
FOXP3+ Regulatory T Cell Compartment Is Altered in Children With Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children.

Front Immunol. 2019-1-22

[5]
Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes.

Diabetes. 2021-6

[6]
Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

J Immunol. 2016-11-15

[7]
Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

J Mol Cell Biol. 2011-11-24

[8]
Transient Depletion of Foxp3 Regulatory T Cells Selectively Promotes Aggressive β Cell Autoimmunity in Genetically Susceptible DEREG Mice.

Front Immunol. 2021

[9]
Exploring CCR5 + T regulatory cell subset dysfunction in type 1 diabetes patients: implications for immune regulation.

Immunol Res. 2024-10

[10]
Differences in Maturation Status and Immune Phenotypes of Circulating Helios and Helios Tregs and Their Disrupted Correlations With Monocyte Subsets in Autoantibody-Positive T1D Individuals.

Front Immunol. 2021

引用本文的文献

[1]
Assessing Implantation Sites for Pancreatic Islet Cell Transplantation: Implications for Type 1 Diabetes Mellitus Treatment.

Bioengineering (Basel). 2025-5-9

本文引用的文献

[1]
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.

Sci Transl Med. 2024-5-8

[2]
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

JCI Insight. 2024-2-8

[3]
Chimeric Antigen Receptor (CAR)-Based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches.

Stem Cell Rev Rep. 2024-4

[4]
Proinflammatory plasticity towards Th17 paradigm of regulatory T cells consistent with elevated prevalence of TGFBR2 variants in elderly patients with primary immune thrombocytopenia.

BMC Immunol. 2023-4-7

[5]
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents.

Pediatr Diabetes. 2022-12

[6]
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.

Lancet Diabetes Endocrinol. 2022-10

[7]
Boosting regulatory T cell function for the treatment of autoimmune diseases - That's only half the battle!

Front Immunol. 2022

[8]
Possible Relationship between the HLA-DRA1 Intron Haplotype of Three Single-Nucleotide Polymorphisms in Intron 1 of the HLA-DRA1 Gene and Autoantibodies in Children at Increased Genetic Risk for Autoimmune Type 1 Diabetes.

Immunohorizons. 2022-8-18

[9]
Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor.

Signal Transduct Target Ther. 2022-7-22

[10]
Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes.

Int J Mol Sci. 2022-4-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索